Cambridge, Mass.– ConcertAI has launched a new AI-powered platform, Precision Suite™, aimed at transforming how healthcare and life sciences organizations generate insights, streamline clinical trials, and bring oncology therapies to market. Built on its proprietary CARAai™ platform and leveraging its expansive Oncology Data, the suite promises faster, more cost-effective decision-making across the enterprise.
The Precision Suite represents a new generation of generative and agentic AI tools. ConcertAI said the technology can cut clinical insight generation time in half and potentially save clients millions in operational costs. At launch, the suite includes three specialized applications: Precision Explorer™, Precision Trials™, and Precision GTM™—each targeting a specific part of the drug development and commercialization lifecycle.
Precision Explorer™ supports medical affairs and health outcomes teams by offering near-instant insights into oncology data. It simplifies cohort creation, outcomes analysis, and hypothesis testing, helping customers stay compliant with ASCO® standards while speeding up research timelines.
Precision Trials™ focuses on clinical trial operations. It uses dynamic AI agents to assist in site selection, patient recruitment, and trial design. According to ConcertAI, it can significantly reduce amendments and trial delays, potentially saving over $4 million on mid- to late-stage trials.
Precision GTM™ is tailored for oncology commercialization efforts. It integrates clinical, claims, and social determinants of health data to help life sciences brands monitor treatment patterns and provider behaviors in real time—enabling faster, more effective go-to-market strategies.
At the core of the suite is Precision360™, a real-world data (RWD) engine that combines electronic medical records, genomic data, insurance claims, and social factors. Updated weekly, it delivers real-time, AI-curated insights even from unstructured datasets, enhancing both speed and accuracy in oncology research.
“Precision Suite is a testament to our commitment to innovation and patient-first outcomes,” said Eron Kelly, CEO of ConcertAI. “These SaaS products, built on the CARAai platform, are designed to deliver actionable insights quickly and cost-effectively.”
Jeff Elton, Ph.D., Vice Chairman of ConcertAI, emphasized the company’s shift toward broader enterprise solutions. “This launch marks our evolution from providing specialized tools to delivering scalable SaaS platforms that redefine how life sciences and healthcare organizations operate.”
Precision Explorer™ and Precision Trials™ will be available on June 30, with Precision GTM™ set to launch by July 31. With this release, ConcertAI, which currently supports 75% of the top life sciences companies and over half of the world’s leading healthcare providers, strengthens its position as a frontrunner in oncology-focused AI solutions.
